NATIONAL
CALIFORNIA
VENTURA
mechanism
- Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors (lipid hormones which have a wide range of effects throughout the body); has antipyretic, analgesic, and anti-inflammatory properties
indications
- Management of acute pain
contraindications
- History of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs
- Cerebrovascular bleeding or other bleeding disorders
- Active gastric/duodenal/peptic ulcer, active GI bleeding
- Inflammatory bowel disease
- Uncontrolled heart failure
dosing
Adult:
Weight ≥50 kg and <65 years of age:
IV: 30 mg
IM: 60 mg
IM: 60 mg
Weight <50 kg or ≥65 years of age:
IV: 15 mg
IM: 30 mg
IM: 30 mg
Pediatric:
IV, IM: 0.5 mg/kg; maximum dose: 30 mg
administration
IM: Administer slowly and deeply into the muscle
IV: Administer IV bolus over a minimum of 15 seconds
IV: Administer IV bolus over a minimum of 15 seconds
onset
30 minutes
peak
2 to 3 hours
duration
4 to 6 hours
notes
- Side effects: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic and gastrointestinal events.
dosage form
Injection Solution: 15 mg/mL (1 mL); 30 mg/mL (1 mL); 60 mg/2 mL (2 mL)
brand name
Toradol
adverse reactions
- Cardiovascular
- Increased risk of serious adverse cardiovascular events, including acute myocardial infarction (MI) and cerebrovascular accident
- Hypertension
- Heart failure
- Gastrointestinal
- GI inflammation
- GI hemorrhage
- GI ulcer
- GI perforation
- Hematologic
- Prolonged bleeding time
- Hemorrhage
- Hemolytic anemia
- Thrombocytopenia (low platelets)
- Hypersensitivity reactions
- Angioedema
- Urticaria
- Stevens-Johnson syndrome (rare serious disorder of the skin and mucous membranes)
- Kidney
- Acute kidney injury
structure
